These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 2891995

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A seven days course of eflornithine for relapsing Trypanosoma brucei gambiense sleeping sickness.
    Khonde N, Pépin J, Mpia B.
    Trans R Soc Trop Med Hyg; 1997; 91(2):212-3. PubMed ID: 9196773
    [Abstract] [Full Text] [Related]

  • 9. Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo.
    Balasegaram M, Harris S, Checchi F, Ghorashian S, Hamel C, Karunakara U.
    Bull World Health Organ; 2006 Oct; 84(10):783-91. PubMed ID: 17128358
    [Abstract] [Full Text] [Related]

  • 10. Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis.
    Chappuis F, Udayraj N, Stietenroth K, Meussen A, Bovier PA.
    Clin Infect Dis; 2005 Sep 01; 41(5):748-51. PubMed ID: 16080099
    [Abstract] [Full Text] [Related]

  • 11. Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: A critical appraisal of 23 years of experience in the Democratic Republic of Congo.
    Kazumba LM, Kaka JT, Ngoyi DM, Tshala-Katumbay D.
    PLoS Negl Trop Dis; 2018 Jun 01; 12(6):e0006504. PubMed ID: 29897919
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [The use of difluoromethylornithine in congenital trypanosomiasis due to Trypanosoma brucei-gambiense].
    Pepin J, Guern C, Milord F, Ethier L, Bokelo M, Schechter PJ.
    Med Trop (Mars); 1989 Jun 01; 49(1):83-5. PubMed ID: 2498607
    [Abstract] [Full Text] [Related]

  • 14. Eflornithine for the treatment of human African trypanosomiasis.
    Burri C, Brun R.
    Parasitol Res; 2003 Jun 01; 90 Supp 1():S49-52. PubMed ID: 12811548
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage Trypanosoma brucei gambiense sleeping sickness.
    Jansson-Löfmark R, Na-Bangchang K, Björkman S, Doua F, Ashton M.
    Antimicrob Agents Chemother; 2015 Feb 01; 59(2):1299-307. PubMed ID: 25512417
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Melarsoprol sensitivity profile of Trypanosoma brucei gambiense isolates from cured and relapsed sleeping sickness patients from the Democratic Republic of the Congo.
    Pyana Pati P, Van Reet N, Mumba Ngoyi D, Ngay Lukusa I, Karhemere Bin Shamamba S, Büscher P.
    PLoS Negl Trop Dis; 2014 Oct 01; 8(10):e3212. PubMed ID: 25275572
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.